We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA Tip Sparks SEC Biopure Investigation

Law360 (October 10, 2005, 12:00 AM EDT) -- A Securities and Exchange Commission lawsuit filed against medical technology company Biopure was prompted by a tip from the Food and Drug Administration, according to SEC officials.

The SEC said it initiated the investigation into Biopure after receiving a communication from the FDA regarding potentially misleading and erroneous statements made by Biopure to its investors.

The SEC filed a lawsuit against Biopure in September alleging that “in 2003, Biopure Corporation and its chief executive officer, head of regulatory affairs and general counsel engaged in a fraudulent...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.